Switch theme
Sign up to access all valuation multiples
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
1989
60
LTM Revenue $5.3M
LTM EBITDA -$44.8M
$194M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Armata Pharmaceuticals has a last 12-month revenue (LTM) of $5.3M and a last 12-month EBITDA of -$44.8M.
In the most recent fiscal year, Armata Pharmaceuticals achieved revenue of n/a and an EBITDA of -$6.8M.
Armata Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Armata Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $5.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$44.8M | XXX | -$6.8M | XXX | XXX | XXX |
| EBITDA Margin | -845% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$44.8M | XXX | -$42.4M | XXX | XXX | XXX |
| EBIT Margin | -845% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$40.6M | XXX | -$18.9M | XXX | XXX | XXX |
| Net Margin | -765% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $85.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Armata Pharmaceuticals's stock price is $2.
Armata Pharmaceuticals has current market cap of $70.6M, and EV of $194M.
See Armata Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $194M | $70.6M | XXX | XXX | XXX | XXX | $-1.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Armata Pharmaceuticals has market cap of $70.6M and EV of $194M.
Armata Pharmaceuticals's trades at n/a EV/Revenue multiple, and -28.3x EV/EBITDA.
Equity research analysts estimate Armata Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Armata Pharmaceuticals has a P/E ratio of -1.7x.
See valuation multiples for Armata Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $70.6M | XXX | $70.6M | XXX | XXX | XXX |
| EV (current) | $194M | XXX | $194M | XXX | XXX | XXX |
| EV/Revenue | 36.5x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -4.3x | XXX | -28.3x | XXX | XXX | XXX |
| EV/EBIT | -4.3x | XXX | -4.6x | XXX | XXX | XXX |
| EV/Gross Profit | 36.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.7x | XXX | -3.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArmata Pharmaceuticals's last 12 month revenue growth is 4%
Armata Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.7M for the same period.
Armata Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Armata Pharmaceuticals's rule of X is -836% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Armata Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -845% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -836% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Protalix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Armata Pharmaceuticals acquired XXX companies to date.
Last acquisition by Armata Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Armata Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Armata Pharmaceuticals founded? | Armata Pharmaceuticals was founded in 1989. |
| Where is Armata Pharmaceuticals headquartered? | Armata Pharmaceuticals is headquartered in United States of America. |
| How many employees does Armata Pharmaceuticals have? | As of today, Armata Pharmaceuticals has 60 employees. |
| Who is the CEO of Armata Pharmaceuticals? | Armata Pharmaceuticals's CEO is Dr. Deborah L. Birx, M.D.. |
| Is Armata Pharmaceuticals publicy listed? | Yes, Armata Pharmaceuticals is a public company listed on ASE. |
| What is the stock symbol of Armata Pharmaceuticals? | Armata Pharmaceuticals trades under ARMP ticker. |
| When did Armata Pharmaceuticals go public? | Armata Pharmaceuticals went public in 1994. |
| Who are competitors of Armata Pharmaceuticals? | Similar companies to Armata Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Armata Pharmaceuticals? | Armata Pharmaceuticals's current market cap is $70.6M |
| What is the current revenue of Armata Pharmaceuticals? | Armata Pharmaceuticals's last 12 months revenue is $5.3M. |
| What is the current revenue growth of Armata Pharmaceuticals? | Armata Pharmaceuticals revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Armata Pharmaceuticals? | Current revenue multiple of Armata Pharmaceuticals is 36.5x. |
| Is Armata Pharmaceuticals profitable? | Yes, Armata Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Armata Pharmaceuticals? | Armata Pharmaceuticals's last 12 months EBITDA is -$44.8M. |
| What is Armata Pharmaceuticals's EBITDA margin? | Armata Pharmaceuticals's last 12 months EBITDA margin is -845%. |
| What is the current EV/EBITDA multiple of Armata Pharmaceuticals? | Current EBITDA multiple of Armata Pharmaceuticals is -4.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
